Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Active specific immunotherapy: PEM as a potential target molecule

J Burchell1, R Graham, J Taylor-Papadimitriou

  • 1Imperial Cancer Research Fund, London.

Cancer Surveys
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Restorative dentistry: A half century of success.

British dental journal·2016
Same author

British Thoracic Society guidelines for the investigation and management of pulmonary nodules.

Thorax·2015
Same author

Predicting distress among people who care for patients living longer with high-grade malignant glioma.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2015
Same author

Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer.

British journal of cancer·2013
Same author

Cellular transformation by chemicals and oncogernes gene transfer and phenotypic changes.

Cytotechnology·2012
Same author

Management of melanomas in primary care.

The British journal of dermatology·2010
Same journal

Future directions: bladder cancer.

Cancer surveys·2004
Same journal

Radiotherapy and chemotherapy for invasive bladder cancer.

Cancer surveys·2004
Same journal

The role of surgery in the multimodality treatment of bladder cancer.

Cancer surveys·2004
Same journal

Clonal development of bladder cancer and its relevance to the clinical potential of HLA antigen and TP53 based gene therapy.

Cancer surveys·2004
Same journal

Clinical evaluation of immunotherapy: are there differences between papillary and flat in situ bladder cancer?

Cancer surveys·2004
Same journal

Molecular biological changes in bladder cancer.

Cancer surveys·2004
See all related articles

Polymorphic epithelial mucin, a target in cancer, is highly immunogenic and upregulated in most carcinomas. Its unique structure and ability to elicit immune responses make it a promising candidate for active specific immunotherapy (ASI).

Area of Science:

  • Immunology
  • Oncology
  • Biochemistry

Background:

  • Understanding biological mechanisms enhances clinical applications.
  • Tumor-associated antigens (TAAs) and immune recognition are key for cancer therapies.
  • Polymorphic epithelial mucin (PEM) is expressed on most carcinomas and is highly immunogenic.

Purpose of the Study:

  • To explore the potential of PEM as a target molecule for active specific immunotherapy (ASI).
  • To identify the molecular mechanisms involved in antigen presentation and immune recognition of PEM.

Main Methods:

  • Analysis of PEM expression patterns in carcinomas.
  • Investigation of PEM glycosylation and epitope exposure.
  • Evaluation of PEM's structural characteristics for immune cell interaction.

Related Experiment Videos

  • Assessment of PEM's capacity to induce HLA-unrestricted killing in cancer patients.

    • Main Results:

    • PEM is upregulated in most carcinomas.
    • Aberrant glycosylation of PEM exposes cryptic epitopes.
    • PEM's tandem repeat structure provides multiple epitopes.
    • PEM's surface-exposed structure facilitates immune cell encounter.
    • PEM elicits HLA-unrestricted killing in cancer patients, indicating broad applicability.

    Conclusions:

    • PEM possesses ideal characteristics for ASI targeting.
    • ASI utilizing PEM offers a potential therapeutic strategy for a wide range of individuals with carcinomas.